摘要
目的：探讨左卡尼汀能否改善维持性血液透析（MHD）患者炎症及营养状况。方法选取2013年6月至2015年6月在吕梁市人民医院行MHD治疗的尿毒症患者80例，将其随机分为对照组与研究组，各40例。对照组行常规营养治疗，研究组在营养治疗基础上予以左卡尼汀1 g静脉滴注，3次/周，持续用药4个月，比较两组血清白蛋白（Alb）、前白蛋白（PA）、转铁蛋白（TRF）、血红蛋白（Hb）、血脂、体格及炎症指标C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白介素-6（IL-6）、丙二醛（MDA）等变化。结果治疗后研究组Alb、PA、TRF、Hb、血脂、体重指数（BMI）、上臂肌围（MAMC）、肱三头肌处皮褶厚度（TSF）等均高于治疗前及对照组（P〈0.05）；治疗后研究组CRP、TNF-α、IL-6等浓度均低于治疗前及对照组（P〈0.05），但两组治疗后MDA比较差异无统计学意义（P〉0.05）。结论行MHD治疗的尿毒症患者辅以左卡尼汀治疗可减轻炎症反应、改善患者营养状况。
ObjectiveTo investigate whether L-carnitine can improve inflammatory and nutritional status of patients who underwent maintenance hemodialysis or not.Methods 80 patients with uremia who underwent MHD were randomly divided into two groups,40 cases in each group,the control group applied conventional nutritional therapy,while the study group treated with Levocarnitine 1 g intravenous nutrition therapy, based on three times/week for 4 months,compared Alb, PA, TRF, Hb, blood lipids, physical and inflammatory markers CRP,TNF-α,IL-6, MDA changes.Results After treatment, Alb, PA, TRF, Hb, serum lipids,BMI, MAMC, TSF in the study group are higher than before the treatment and control group （P〈0.05）; after treatment, CRP, TNF-α IL-6 in the study group were lower than before treatment and control group （P〈0.05）, but the difference of MDA between two groups showed not statistically significant （P〉0.05）. Conclusions For patients with uremic who underwent MHD, supplement L-carnitine therapy can reduce inflammation and improve the nutritional status of patients.
出处
《中国临床实用医学》
2016年第4期32-34,共3页
China Clinical Practical Medicine
